-transparent.png){kind=logo}
Patients with stage A2 carcinoma of the prostate are a heterogeneous population and not all of them progress to clinically manifest disease. We found a similar variability in terms of the pathological findings in a group of 34 patients with stage A2 disease undergoing pelvic lymphadenectomy and radical prostatectomy. While 8 patients (24 per cent) had metastatic disease on staging lymphadenectomy, 9 patients (27 per cent) had negative lymphadenectomy, with minimal or no residual tumor in the radical specimen. The histologic grade and extent of tumor on transurethral resection did not predict reliably patients with stage A2 disease and minimally invasive cancer at radical prostatectomy. It appears that present criteria for separating stage A tumors into focal and diffuse categories are adequate for selecting therapy for patients with incidental carcinoma of the prostate.
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
July 1982,
Urology,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
December 1991,
The American journal of surgical pathology,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
January 1992,
Cancer,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
September 1983,
Der Urologe. Ausg. A,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
June 1979,
Urology,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
September 1994,
Histopathology,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
July 1985,
Urology,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
July 1985,
Zhonghua fu chan ke za zhi,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
January 1987,
Nihon Hinyokika Gakkai zasshi. The japanese journal of urology,
H E Parfitt, and
J A Smith, and
J P Seaman, and
R G Middleton
January 1983,
The Prostate,
